MLYS — Mineralys Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $947.65m
- $604.62m
- 29
- 21
- 81
- 40
Annual cashflow statement for Mineralys Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.43 | -19.4 | -29.8 | -71.9 | -178 |
| Depreciation | |||||
| Non-Cash Items | 0.483 | 0.764 | -0.194 | -1.8 | 1.93 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.48 | 4.08 | 0.772 | -7.47 | 9.52 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -2.46 | -14.6 | -29.2 | -81.2 | -166 |
| Capital Expenditures | — | — | — | — | -0.096 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -21.8 | -160 | 115 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | — | -21.8 | -160 | 115 |
| Financing Cash Flow Items | — | — | -1.63 | — | -0.435 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.83 | 23.8 | 128 | 203 | 116 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.37 | 9.25 | 77 | -38.4 | 64.8 |